Search

Your search keyword '"Tretiakova, Maria S."' showing total 8 results
Start Over Author "Tretiakova, Maria S." Journal american journal of surgical pathology
8 results on '"Tretiakova, Maria S."'

1. Challenges in Pathologic Staging of Renal Cell Carcinoma

Author

Williamson, Sean R., primary, Rao, Priya, additional, Hes, Ondrej, additional, Epstein, Jonathan I., additional, Smith, Steven C., additional, Picken, Maria M., additional, Zhou, Ming, additional, Tretiakova, Maria S., additional, Tickoo, Satish K., additional, Chen, Ying-Bei, additional, Reuter, Victor E., additional, Fleming, Stewart, additional, Maclean, Fiona M., additional, Gupta, Nilesh S., additional, Kuroda, Naoto, additional, Delahunt, Brett, additional, Mehra, Rohit, additional, Przybycin, Christopher G., additional, Cheng, Liang, additional, Eble, John N., additional, Grignon, David J., additional, Moch, Holger, additional, Lopez, Jose I., additional, Kunju, Lakshmi P., additional, Tamboli, Pheroze, additional, Srigley, John R., additional, Amin, Mahul B., additional, Martignoni, Guido, additional, Hirsch, Michelle S., additional, Bonsib, Stephen M., additional, and Trpkov, Kiril, additional

Published
2018
Full Text
View/download PDF

2. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized

Author

McKenney, Jesse K., primary, Wei, Wei, additional, Hawley, Sarah, additional, Auman, Heidi, additional, Newcomb, Lisa F., additional, Boyer, Hilary D., additional, Fazli, Ladan, additional, Simko, Jeff, additional, Hurtado-Coll, Antonio, additional, Troyer, Dean A., additional, Tretiakova, Maria S., additional, Vakar-Lopez, Funda, additional, Carroll, Peter R., additional, Cooperberg, Matthew R., additional, Gleave, Martin E., additional, Lance, Raymond S., additional, Lin, Dan W., additional, Nelson, Peter S., additional, Thompson, Ian M., additional, True, Lawrence D., additional, Feng, Ziding, additional, and Brooks, James D., additional

Published
2016
Full Text
View/download PDF

3. Tuberous Sclerosis–associated Renal Cell Carcinoma

Author

Guo, Juan, primary, Tretiakova, Maria S., additional, Troxell, Megan L., additional, Osunkoya, Adeboye O., additional, Fadare, Oluwole, additional, Sangoi, Ankur R., additional, Shen, Steven S., additional, Lopez-Beltran, Antonio, additional, Mehra, Rohit, additional, Heider, Amer, additional, Higgins, John P., additional, Harik, Lara R., additional, Leroy, Xavier, additional, Gill, Anthony J., additional, Trpkov, Kiril, additional, Campbell, Steven C., additional, Przybycin, Christopher, additional, Magi-Galluzzi, Cristina, additional, and McKenney, Jesse K., additional

Published
2014
Full Text
View/download PDF

4. Is GATA3 Expression Maintained in Regional Metastases?

Author

Zhao, Lei, primary, Antic, Tatjana, additional, Witten, Daniela, additional, Paner, Gladell P., additional, Taxy, Jerome B., additional, Husain, Aliya, additional, Gwin, Katja, additional, Mirza, M. Kamran, additional, Lingen, Mark W., additional, and Tretiakova, Maria S., additional

Published
2013
Full Text
View/download PDF

8. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.

Author

Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M, Vogelzang NJ, Lin F, Krausz T, Teh BT, and Yang XJ

Subjects
Carcinoma, Papillary pathology, Carcinoma, Renal Cell pathology, Gene Expression Profiling, Humans, Immunohistochemistry, Kidney Neoplasms pathology, Oligonucleotide Array Sequence Analysis, RNA, Messenger analysis, Biomarkers, Tumor analysis, Carcinoma, Papillary enzymology, Carcinoma, Renal Cell enzymology, Kidney Neoplasms enzymology, Racemases and Epimerases biosynthesis
Abstract

Alpha-methylacyl-CoA racemase (AMACR) was first discovered by using cDNA microarray technology as a molecular marker for prostate cancer. Our recent microarray analysis of renal cell carcinomas showed a significant increase of AMACR mRNA levels in papillary renal cell carcinomas, but not in other subtypes. To investigate the value of this marker in pathologic diagnosis, we analyzed AMACR mRNA levels in cDNA microarrays from 70 kidney tumors. Furthermore, we evaluated the AMACR expression in 165 kidney tumors on tissue microarrays and 51 papillary carcinomas of other organs by immunohistochemistry. AMACR mRNA was significantly overexpressed in 7 of 8 papillary renal cell carcinomas with an average of 5.2-fold increase, and only in 2 of 62 nonpapillary kidney tumors. Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100%), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15%) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. All chromophobe (0 of 18) and sarcomatoid components of renal cell carcinomas (0 of 15) were negative for AMACR. Weak or focal AMACR immunoreactivity was detected in only 4 of 51 (8%) papillary carcinomas arising in other organs (2 of 14 thyroid, 2 of 13 lung, 0 of 6 breast, 0 of 6 endometrium, 0 of 6 ovary, and 0 of 6 pancreas). Using a combination of cDNA microarrays, tissue microarrays, and immunohistochemistry, we identified AMACR as a marker for papillary renal cell carcinoma, which could be valuable in subclassification of renal cell carcinomas and in the differential diagnosis of a metastatic papillary carcinoma.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results